Časopisi po područjima
Izvorni znanstveni članak
Intravenous rt-PA Thrombolytic Therapy in Fifty-Six Ischemic Stroke Patients - A Prospective follow-Up Study
Puni tekst: pdf (840 KB),
Str. 289 - 297
Intravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA) has recently reached the goal of becoming standard therapy in the acute stage of ischemic stroke in many countries. This appears to be one of the first pilot study reports from the region of Central and Eastern Europe. From January 1998 till October 2002, 56 consecutive patients underwent rt-PA thrombolysis at the University Department of Neurology, Nitra University Hospital, Slovakia. Selection criteria for the study were based on the NINDS study, with emphasis on the 3-hour therapeutic window. The mean baseline NIHSS wasR14.5, mean therapeutic interval 167 minutes, and mean intravenous rt-PA dose 0.7 mg/kg body weight. AtR3 months, mRS 0-1 was recorded in 33.9%, mRS 2-3 in 37.5%, and mRS 4-5 in 16.1% of study patients. Clinically relevant mRS 0-2 was achieved in 44.6% of study patients. The mortality was 12.5%. The rate of symptomatic and fatal intracerebral hemorrhage was 8.9% and 5.3%, respectively. Asymptomatic hemorrhagic transformation of a benign course was relatively frequently recorded (19.6%). Results of the study showed our stroke patients treated with intravenous rt-PA to have a favorable prognosis, and were comparable with those reported from the NINDS study and recent clinical studies.
Cerebrovascular accident - drug therapy; Brain ischemia - drug therapy; Fibrinolytic agents - administration and dosage; Thrombolysis; Acute disease; Follow up studies
Registracija novih korisnika
Zaboravili ste lozinku?